TY  - JOUR

T1  - Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

JO  - PharmacoEconomics

PY  - 2021/06/19

AU  - Pennington B

AU  - Alshreef A

AU  - Flight L

AU  - Metry A

AU  - Poku E

AU  - Hykin P

AU  - Sivaprasad S

AU  - Prevost AT

AU  - Vasconcelos JC

AU  - Murphy C

AU  - Kelly J et al

ED  - 

DO  - DOI: 10.1007/s40273-021-01057-y

PB  - Springer Science and Business Media LLC

Y2  - 2024/12/21

ER  -